Introduction
============

Schizophrenia is ranked among the top 25 leading causes of disability worldwide in 2013.[@b1-ndt-12-357] Despite its low lifetime prevalence (median 4.0 per 1,000 persons[@b2-ndt-12-357]) and point prevalence range from 2.6 to 6.7 per 1,000,[@b3-ndt-12-357],[@b4-ndt-12-357] health, social, and economic burden related to schizophrenia has been tremendous, not only for patients but also for families, other caregivers, and the wider society. The World Health Organization estimated that direct costs of schizophrenia in Western countries range from 1.6% to 2.6% of total health care expenditures, which in turn account for between 7% and 12% of the gross national product (GNP).[@b5-ndt-12-357] In the US, the economic burden of schizophrenia is found to be more than US\$60 billion per year.[@b6-ndt-12-357] Albeit the increasing evidence base, this multifaceted burden of schizophrenia remains underestimated.[@b7-ndt-12-357] The substantial burden imposed by schizophrenia has been linked to the early onset of the disease and its incurable nature with persisting symptoms.[@b8-ndt-12-357] Societies and communities find it increasingly difficult to offer support to schizophrenia patients through family and social bonds.[@b9-ndt-12-357]

With productivity losses as the largest component of the overall societal cost of schizophrenia,[@b10-ndt-12-357] an economic burden study which often incorporates both direct and indirect costs serves as a useful source. Economic burden studies have primarily been employed to advise policymakers on resources allocation.[@b11-ndt-12-357] Economic burden studies, however, vary due to methodology differences and costs included. These include study settings, data sources, epidemiological approaches taken (eg, prevalence- or incidence-based), cost determination method (eg, top-down, bottom-up, or a combination of both), time frame of costs, and perspective (ie, societal or payer), all of which are important factors having substantial impact on the outcomes.

Previous literature review studies were focused on summarizing direct costs associated with schizophrenia.[@b12-ndt-12-357],[@b13-ndt-12-357] There has been a lack of emphasis on methodology details and indirect costs estimation, which prompts the need for a more comprehensive and updated review. This study aims to systematically identify studies focusing on the economic burden of schizophrenia, describe methods and data sources, and summarize the findings of the economic burden of schizophrenia.

Methods
=======

Search strategy and data sources
--------------------------------

A systematic review was performed for economic burden studies in schizophrenia using four electronic databases -- Medline, EMBASE, PsycINFO, and EconLit. The search strategy was based on a broad combined search string "burden OR economic\* OR cost\* OR "cost of illness" OR resource OR expenditure" AND schizophrenia in abstract or title fields to retrieve potentially relevant publications from inception to August 31, 2014. Search strategies were limited to English and humans only.

Study selection
---------------

All identified studies were screened for relevance based on the predefined inclusion criteria. The inclusion criteria were an original research that: 1) reported cost of illness, economic burden, health care expenditure, or resource utilization for schizophrenia and 2) provided information on data sources. Studies on economic evaluation of drug or other treatment, and study population referring to a specific subgroup of schizophrenia patients only were excluded from the analysis.

Two reviewers (HYC, SLT) independently screened the identified studies based on the title and abstract using the aforementioned inclusion criteria. In case of disagreement, this was resolved by discussion between the two reviewers. Thereafter, the full-text of all potentially relevant studies was reviewed. A flow chart that illustrates the selection process is shown in [Figure 1](#f1-ndt-12-357){ref-type="fig"}.

Quality assessment
------------------

Quality assessment is generally a crucial component of a systematic review.[@b14-ndt-12-357] However, our review is focused mainly on describing the diversity of the methodology used in economic burden studies. Therefore, quality assessment is not relevant for our review.

Data extraction
---------------

A standardized data extraction form was used to extract data of all eligible studies. The data were extracted by HYC or SLT. In case of doubt, there was a consultation process to base the extraction upon consensus. Where possible, country, perspective, currency, pricing year, study design and approach, cost estimation methods, setting, study period/duration, sample size, cost components, data sources, and cost estimates were defined precisely.

For costs comparison across studies, the cost estimates were converted to 2013 US dollars, based on country-specific consumer price indices[@b15-ndt-12-357] and exchange rate.[@b16-ndt-12-357] If the year of the cost data was not reported, it was assumed to be the publication year of the article. Furthermore, the total cost estimates in term of gross domestic product (GDP) or GNP were extracted as originally published. To facilitate further comparisons across studies in terms of the magnitude of the total estimates relative to the GDP, the total cost as percentage of GDP 2013 of the country[@b15-ndt-12-357] was estimated.

Methodological and costing approach
-----------------------------------

The study design was classified as retrospective, prospective, cross-sectional, or modeling-based; subsequently, the approach undertaken either as prevalence- or incidence-based was defined. Prevalence-based studies estimate the costs of all disease cases (new as well as pre-existing) in a given year.[@b17-ndt-12-357] They include medical care costs and morbidity costs of schizophrenia within the study year.[@b18-ndt-12-357] Incidence-based studies, on the other hand, estimate the lifetime costs of a disease from its onset to its termination, which include the discounted morbidity and mortality costs for the incident cohort, usually calculated based on the year when schizophrenia first appeared.[@b18-ndt-12-357]

To quantify the resources used, approaches commonly used are the top-down and bottom-up. The top-down approach estimates economic costs by using aggregate data on mortality, morbidity, hospital admissions, general practice consultations, disease-related costs, and other health-related indicators.[@b18-ndt-12-357] Generally, this information is collected from national health care statistics, patient registers, and so on.[@b18-ndt-12-357] The bottom-up approach calculates the resources utilization and productivity loss at the level of patient or individual.[@b18-ndt-12-357],[@b19-ndt-12-357] The mean per-person costs are usually then extrapolated to the whole population with relevant epidemiological data.[@b18-ndt-12-357]

Cost components and data sources
--------------------------------

Broadly, the economic burden of schizophrenia can be reported as direct (medical and nonmedical), indirect costs, and intangible costs. Direct medical costs are expenditure for hospital inpatient care, physician inpatient care, physician outpatient care, emergency department visits, community-based care, nursing home care, long-term institutional care, rehabilitation care, specialists' and other health professionals' care, diagnostic tests, prescription drugs, and medical supplies.[@b20-ndt-12-357] Direct nonmedical costs are the costs of nonhealth care resources, such as transportation, food, and lodging incurred during health care visit,[@b21-ndt-12-357] and cost-associated social services.[@b22-ndt-12-357]

Indirect costs are defined as productivity losses related to morbidity and premature mortality. Morbidity costs represent the monetary value of productivity loss due to absenteeism or sick leave (forgone work productivity), presenteeism (decreased work productivity), unemployment, permanent disability, and early retirement for patients, family members, or caregivers.[@b20-ndt-12-357],[@b23-ndt-12-357]--[@b26-ndt-12-357] On the other hand, mortality cost is defined as the monetary value of lost production due to the premature death of the patient.[@b26-ndt-12-357] In addition, costs associated with other consequences such as incarceration are included.[@b27-ndt-12-357]

The third category of costs is referred to as intangible costs. These relate to the deterioration in quality of life to patients, families, and friends due to other factors, such as pain or suffering.[@b21-ndt-12-357] These costs are extremely difficult to quantify, and therefore are often omitted from economic studies.[@b28-ndt-12-357]

Data sources were further classified into four major groups -- database, chart, interview, and literature. Database is defined as a collection of health data in the form of: 1) population, household, and health survey; 2) surveillance data, including disease-specific registries, census, and national health accounts;[@b15-ndt-12-357] and 3) electronic medical records, administrative, and claims database. Chart includes patient medical record and hospital record. Interview involves patient, caregiver, or health care provider/expert using structured/standardized questionnaire. Literature includes published or unpublished sources and governmental report/document.

Results
=======

Study selection
---------------

The search strategy yielded 6,255 articles, of which 423 duplicates were removed. Of the remaining 5,832 articles, only 64 met the inclusion criteria and were retrieved to be reviewed in full-text. During the full-text screening, a further eight articles were excluded due to review paper (n=3), non-English publication (n=2), conference abstract (n=1), duplicate (n=1), and inadequate information on data sources (n=1). This resulted in a total of 56 relevant articles that were included in this review.

General methodological characteristics
--------------------------------------

The methodological characteristics of the included articles are summarized in [Table 1](#t1-ndt-12-357){ref-type="table"}. These studies were conducted for 24 countries covering four regions (25 in Europe,[@b29-ndt-12-357]--[@b53-ndt-12-357] 16 in America,[@b10-ndt-12-357],[@b54-ndt-12-357]--[@b68-ndt-12-357] 13 in Asia Pacific,[@b11-ndt-12-357],[@b69-ndt-12-357]--[@b80-ndt-12-357] and 2 in Africa[@b81-ndt-12-357],[@b82-ndt-12-357]). More than two-third of the studies (48/56, 86%) were conducted in high-income countries (HIC), for example, the US (n=13), Spain (n=6), Germany (n=5), the UK (n=5), Sweden (n=4), and Australia (n=4).

Of the included studies, it was found that 24 studies[@b10-ndt-12-357],[@b11-ndt-12-357],[@b31-ndt-12-357]--[@b33-ndt-12-357],[@b36-ndt-12-357],[@b39-ndt-12-357],[@b43-ndt-12-357],[@b44-ndt-12-357],[@b52-ndt-12-357],[@b53-ndt-12-357],[@b55-ndt-12-357],[@b57-ndt-12-357]--[@b61-ndt-12-357],[@b63-ndt-12-357],[@b65-ndt-12-357],[@b67-ndt-12-357],[@b68-ndt-12-357],[@b73-ndt-12-357],[@b77-ndt-12-357],[@b79-ndt-12-357] were undertaken at the national level. Over half of the studies (30/56, 54%) were conducted in selected health care institutions,[@b30-ndt-12-357],[@b38-ndt-12-357],[@b47-ndt-12-357],[@b69-ndt-12-357],[@b71-ndt-12-357], [@b74-ndt-12-357]--[@b76-ndt-12-357],[@b78-ndt-12-357],[@b81-ndt-12-357],[@b82-ndt-12-357] one or several provinces/states/counties,[@b29-ndt-12-357],[@b37-ndt-12-357],[@b45-ndt-12-357],[@b48-ndt-12-357],[@b50-ndt-12-357],[@b54-ndt-12-357],[@b56-ndt-12-357],[@b62-ndt-12-357],[@b64-ndt-12-357],[@b66-ndt-12-357],[@b70-ndt-12-357],[@b72-ndt-12-357] specific health care program for schizophrenia patients,[@b34-ndt-12-357],[@b35-ndt-12-357],[@b42-ndt-12-357],[@b46-ndt-12-357],[@b49-ndt-12-357],[@b80-ndt-12-357] and an insurance scheme,[@b51-ndt-12-357] while it was not reported in two studies.[@b40-ndt-12-357],[@b41-ndt-12-357]

Less than half of studies (23/56, 41%) explicitly stated the perspective undertaken. The societal perspective was the most commonly employed (n=16), followed by payer perspective (n=11).

Furthermore, most studies undertook a retrospective (n=24) and prevalence-based (n=53) study design. Only four studies employed an incidence-based approach where two adapted discrete event modeling[@b36-ndt-12-357] and Markov modeling,[@b79-ndt-12-357] respectively. It is noted that Davies and Drummond[@b31-ndt-12-357] adopted both prevalence- and incidence-based design. Only three studies estimated the lifetime costs of schizophrenia using incidence-based approach[@b31-ndt-12-357],[@b79-ndt-12-357] and prevalence-based approach,[@b65-ndt-12-357] while the remaining studies presented the burden measurement as total cost and/or average cost per patient over a specific time period.

Generally, the most commonly used method to determine costs was bottom-up (n=37), followed by top-down (n=12), and a combination of both methods (n=7). Among 19 studies that adapted the top-down method,[@b10-ndt-12-357],[@b11-ndt-12-357],[@b31-ndt-12-357],[@b32-ndt-12-357],[@b36-ndt-12-357]--[@b39-ndt-12-357],[@b43-ndt-12-357],[@b48-ndt-12-357],[@b52-ndt-12-357],[@b53-ndt-12-357],[@b56-ndt-12-357],[@b59-ndt-12-357],[@b60-ndt-12-357],[@b65-ndt-12-357],[@b72-ndt-12-357],[@b73-ndt-12-357],[@b77-ndt-12-357] 16 were conducted using prevalence-based approach at the national level. It is noted that all 16 studies were conducted in HIC -- Japan, South Korea, Taiwan, France, Ireland, the Netherlands, Spain, Sweden, UK, Canada, Puerto Rico, and the US.

Overall description of cost components and data sources for cost estimation
---------------------------------------------------------------------------

Among all included studies, 56 captured direct medical costs, 28 direct nonmedical costs, and 32 indirect costs. Only one study attempted to quantify intangible cost.[@b41-ndt-12-357] Over a third of the studies (21/56, 38%) investigated direct medical, direct nonmedical, and indirect costs of schizophrenia.

An overview of the cost components included and data sources used in the estimation of direct medical, direct nonmedical, and indirect cost among the studies is presented in [Tables 2](#t2-ndt-12-357){ref-type="table"}[](#t3-ndt-12-357){ref-type="table"}--[4](#t4-ndt-12-357){ref-type="table"}. All cost components and data sources used in each study are summarized in the Supplementary table.

Direct medical costs
--------------------

For the estimation of direct medical costs, the majority of the studies, asides from two studies,[@b65-ndt-12-357],[@b72-ndt-12-357] included costs associated with hospitalization (n=45), pharmacy (n=45), outpatient care (n=33), or home- and community-based care (n=31). In general, more than a third of the studies[@b10-ndt-12-357],[@b11-ndt-12-357],[@b32-ndt-12-357],[@b33-ndt-12-357],[@b37-ndt-12-357],[@b38-ndt-12-357],[@b42-ndt-12-357],[@b43-ndt-12-357],[@b48-ndt-12-357], [@b51-ndt-12-357],[@b52-ndt-12-357],[@b54-ndt-12-357]--[@b64-ndt-12-357],[@b66-ndt-12-357]--[@b68-ndt-12-357],[@b73-ndt-12-357],[@b80-ndt-12-357] estimated the utilization data of direct medical cost using database (27/56, 48%), interview (n=20), literature (n=17), and chart (n=12) as the data source.

In 48 studies[@b10-ndt-12-357],[@b11-ndt-12-357],[@b29-ndt-12-357]--[@b59-ndt-12-357],[@b60-ndt-12-357]--[@b65-ndt-12-357],[@b67-ndt-12-357],[@b68-ndt-12-357],[@b70-ndt-12-357],[@b72-ndt-12-357]--[@b74-ndt-12-357],[@b77-ndt-12-357],[@b79-ndt-12-357],[@b80-ndt-12-357] conducted in HIC, database (n=26) and literature (n=16) were most commonly applied as the data source. Claims database was used as the primary data source in ten studies. In contrast, from the eight studies conducted in low- and middle-income countries (LMIC), interview (n=7) was the most commonly used data source for direct medical cost estimation, followed by chart (n=4).

Direct nonmedical costs
-----------------------

A total of 28 studies[@b10-ndt-12-357],[@b11-ndt-12-357],[@b30-ndt-12-357],[@b33-ndt-12-357],[@b36-ndt-12-357],[@b40-ndt-12-357]--[@b42-ndt-12-357],[@b44-ndt-12-357],[@b46-ndt-12-357],[@b47-ndt-12-357],[@b50-ndt-12-357],[@b52-ndt-12-357],[@b53-ndt-12-357],[@b60-ndt-12-357],[@b62-ndt-12-357],[@b67-ndt-12-357]--[@b71-ndt-12-357],[@b74-ndt-12-357],[@b76-ndt-12-357]--[@b79-ndt-12-357],[@b81-ndt-12-357],[@b82-ndt-12-357] estimated the direct nonmedical cost in which homeless shelter (n=18), travel, food, and lodging expenses (n=9), social care (n=7), and suicide-related (n=2) costs were measured. Data sources used to estimate utilization data of these costs were interview (n=12), literature (n=11), database (n=4), and chart (n=2).

In 28 studies that estimated direct nonmedical costs, literature (n=12) and interview (n=8) were the main data sources used in HIC, while interview (n=6) was used in LMIC.

Indirect costs
--------------

In 32 studies that included indirect cost estimates, the human capital approach was used in 27 studies. Friction cost approach was used in two studies in Germany and Canada.[@b33-ndt-12-357],[@b60-ndt-12-357]

To estimate indirect costs, more than half (19/32, 59%) took into account informal care cost. Furthermore, other main components calculated were productivity loss associated with absenteeism (n=14), premature mortality (n=12), and unemployment (n=11). These indirect costs were estimated mainly based on literature (n=19), interview (n=15), and database (n=5) as their data sources.

Literature (n=19) was used as the main data source in studies from HIC, while it was interview (n=6) in studies from LMIC. In addition, it is found that published mean wage was used as the unit cost in the estimation of productivity loss in all studies from HIC, while reported individual wage obtained from the interview performed was used in three studies from LMIC.[@b69-ndt-12-357],[@b71-ndt-12-357],[@b76-ndt-12-357]

Cost estimates of schizophrenia
-------------------------------

Cost estimates from 15 national studies that investigated both direct and indirect costs are presented in [Table 5](#t5-ndt-12-357){ref-type="table"} in terms of cost in US dollars in 2013, and the share of the direct medical cost, direct nonmedical cost, and indirect cost. The total cost estimates reported varied significantly where annual costs for the schizophrenia population in the country reported ranged from US\$94 million in Puerto Rico[@b65-ndt-12-357] to US\$102,396 million in the US.[@b67-ndt-12-357] Furthermore, there was a substantial difference in annual cost estimates in studies conducted in the same country where US\$123 million[@b32-ndt-12-357] to US\$9,134 million[@b39-ndt-12-357] in Sweden and US\$25,452 million[@b57-ndt-12-357] to US\$102,396 million[@b67-ndt-12-357] in the US was found.

Notably, indirect costs contributed to 50%--85% of the overall costs associated with schizophrenia in 12 national studies;[@b10-ndt-12-357],[@b11-ndt-12-357],[@b32-ndt-12-357],[@b36-ndt-12-357],[@b39-ndt-12-357],[@b52-ndt-12-357],[@b57-ndt-12-357],[@b60-ndt-12-357],[@b65-ndt-12-357],[@b67-ndt-12-357],[@b68-ndt-12-357],[@b77-ndt-12-357] only three studies reported otherwise.[@b33-ndt-12-357],[@b43-ndt-12-357],[@b53-ndt-12-357] Similar findings were noted in six studies from LMIC with direct and indirect cost estimates; the contribution of indirect costs to total annual costs is demonstrated to range from 63% to 82% as compared to direct costs,[@b69-ndt-12-357],[@b71-ndt-12-357],[@b76-ndt-12-357],[@b78-ndt-12-357] except for two studies from Nigeria.[@b81-ndt-12-357],[@b82-ndt-12-357] The cost estimates in LMIC are shown in [Table 6](#t6-ndt-12-357){ref-type="table"}.

Only three studies reported the total annual costs incurred by schizophrenia as percentage of GDP[@b70-ndt-12-357],[@b74-ndt-12-357] or GNP[@b68-ndt-12-357] in the country. However, results varied significantly where it was 0.23%--0.36% GDP in Australia, 5.46% GDP in Taiwan, and 2% GNP in the US. In the 15 national studies,[@b10-ndt-12-357],[@b11-ndt-12-357],[@b32-ndt-12-357],[@b33-ndt-12-357],[@b36-ndt-12-357],[@b39-ndt-12-357],[@b43-ndt-12-357],[@b52-ndt-12-357],[@b53-ndt-12-357],[@b57-ndt-12-357],[@b60-ndt-12-357],[@b65-ndt-12-357],[@b67-ndt-12-357],[@b68-ndt-12-357],[@b77-ndt-12-357] the total cost as % GDP in the country estimated was found to range from 0.02% in UK[@b36-ndt-12-357] to 1.65% in Sweden.[@b39-ndt-12-357]

Discussion
==========

This is the first systematic review summarizing the methodologies used in estimating economic burden of schizophrenia globally. We focused on describing the methodology adopted and its practice. Trends in adopting certain methodological aspects were observed, attributed to data availability and accessibility, methodological feasibility, and practicality.

Our study revealed that the data sources used for estimating economic burden of schizophrenia were distinctively different between HIC and LMIC. We found that electronic database was the most common data source for HIC as it provided more representative cost estimates given its large sample size. This was not the case for LMIC where electronic database was less available and accessible, leading to the use of interview and chart review for data collection. Even though interview is resource-intensive, it can capture out-of-pocket expenditures. We believe that the use of multiple data sources is needed to enhance comprehensiveness of cost findings since one single data source will not be able to capture all relevant costs.

Of all studies reviewed, prevalence-based approach was the most frequently used. However, for chronic illnesses such as schizophrenia, incidence-based approach is more relevant,[@b83-ndt-12-357] by informing the lifetime costs potentially saved by averting a case of schizophrenia. Prevalence-based studies, however, could be interpreted as a snapshot of the costs incurred by schizophrenia in a year.[@b83-ndt-12-357] Nevertheless, less data and fewer assumptions required for a prevalence-based approach enhanced its practicality.[@b83-ndt-12-357] It is recommended for future economic burden studies to implement both study designs alongside to obtain complementary findings.

Our findings revealed indirect costs contributed most to the overall costs in economic burden studies conducted from societal perspective. Economic burden studies conducted from a narrower perspective, excluding indirect costs, consequently underestimated costs incurred by schizophrenia substantially. Unless the purpose of economic burden study is to serve as evidence for payers only, the inclusion of indirect costs is warranted to measure economic burden impacted by schizophrenia on the society. Nevertheless, the accuracy of indirect costs is subjected to the cost estimation method applied.

In estimating indirect costs, human capital method was found to be more prevalent than friction cost method in our review. In view of the theory behind both methods, friction cost method appears to yield more realistic estimates than human capital method in chronic diseases, such as schizophrenia.[@b84-ndt-12-357] This is because long-term absences due to schizophrenia or associated mortality will be covered by a person drawn from the pool of unemployed.[@b85-ndt-12-357] Therefore, there is a little loss to society overall.[@b85-ndt-12-357] Often, due to its practicality and broad scope, human capital method might have been chosen. Considering the strengths and limitations of both methods,[@b86-ndt-12-357] it is highly recommended to use both methods when conducting economic burden analysis to provide comprehensive indirect cost estimates, and thus its comparability can be enhanced.

In addition to the cost components typically captured, special cost components were captured in some studies in our review,[@b10-ndt-12-357],[@b11-ndt-12-357],[@b30-ndt-12-357],[@b36-ndt-12-357],[@b40-ndt-12-357]--[@b42-ndt-12-357],[@b46-ndt-12-357],[@b47-ndt-12-357],[@b49-ndt-12-357],[@b50-ndt-12-357],[@b52-ndt-12-357],[@b53-ndt-12-357],[@b60-ndt-12-357],[@b67-ndt-12-357],[@b70-ndt-12-357],[@b74-ndt-12-357],[@b78-ndt-12-357],[@b79-ndt-12-357],[@b82-ndt-12-357] namely, homeless shelter, law enforcement, and accident and damage. In a broader perspective, the prevalence of homelessness is potentially linked to social isolation, stigmatization, and caregiver burden; violent behavior associated with schizophrenia could have contributed to the costs of law enforcement and accident and damage. These special cost components were somewhat specific to schizophrenia which can have a substantial impact on the society in terms of economic and humanistic burden.[@b87-ndt-12-357] While not all studies in our analysis valued these cost components, we highlight its existence of this kind of special cost component and its contribution to overall economic burden of schizophrenia.

Our systematic review showed that all included studies revealed substantial economic impact associated with schizophrenia. The annual costs were estimated to be in the range of US\$94 million to US\$102 billion, which translated into 0.02%--5.46% of GDP. In addition, the economic burden reported in slightly less than half of the national studies (7/15, 47%) ranged between 0.30% and 0.60% GDP, consistent with those reported in Asia Pacific region. However, there were some extremely low estimates particularly in countries with tax-funded health care during the study period, namely, Sweden, the UK, and Puerto Rico. Therefore, this discrepancy was likely due to the differences in health care system, pattern of resource utilization, scope of cost components, diversity of the sampled populations, and data sources used.[@b20-ndt-12-357],[@b88-ndt-12-357] Nevertheless, this magnitude of economic burden demonstrated that schizophrenia has been inadequately treated which underscores the need for a comprehensive approach to controlling its impact.

This review is useful to inform health policymakers on the current status of economic burden studies in schizophrenia. In addition, this review advocates increasing the awareness of public and policymakers to recognize schizophrenia as a burdensome illness. In turn, more resources need to be allocated in treating the illness and develop new lines of policy-oriented research targeted on schizophrenia.

Our systematic review is different from previous review studies in a number of aspects. Previous review studies focused only on quantitative findings on the economic burden of schizophrenia.[@b12-ndt-12-357],[@b13-ndt-12-357] They did not provide a summary of the methodologies undertaken and discuss the implications of methodology on the findings. This present review provides an overall comprehensive comparison of methodologies used in economic burden studies, which could generate insightful information for future economic studies in adopting the relevant methodological approach. In addition, we performed a review using a systematic approach following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement, which led to a better and more comprehensive summary of the overall economic burden studies in current literature.

A limitation of this systematic review is the inclusion of only English literature. It was clear that a number of literatures have been published in local languages, which are evident to be more prevalent among LMIC.[@b89-ndt-12-357] We intentionally excluded non-English literature because of our limited capacity to understand non-English language. During our exhaustive search, we identified two non-English articles which might have provided more information if we had broadened our inclusion criteria.

Our study highlighted the variety of methodological approaches in estimating the economic burden of schizophrenia. On a similar note, it is also crucial to report explicitly on cost components incorporated and their calculations. In order to improve the comparison and interpretation of the economic burden findings, we recognize and recommend the need to develop a guidance document in both the conduct and reporting of future studies for estimating the economic burden of schizophrenia.

Conclusion
==========

Despite the wide variation in methodologies and cost components in studies reviewed, there is a general consensus which can be drawn that schizophrenia imposes a substantial economic burden on society mainly driven by high indirect costs. Understanding the magnitude of the wide-ranging economic and social burden of schizophrenia among policymakers enables informed decisions to be made by establishing health care priorities and allocating scarce resources for this highly disabling yet under-recognized mental health disease.
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###### 

Methodological characteristics of the included studies

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                                    Country                      Perspective      Cost (currency, year)                                 Study design                          Study approach   General cost estimation method   Indirect cost estimation method   Setting                                                                                   Study period/duration                     Sample size (n)
  ----------------------------------------- ---------------------------- ---------------- ----------------------------------------------------- ------------------------------------- ---------------- -------------------------------- --------------------------------- ----------------------------------------------------------------------------------------- ----------------------------------------- -----------------
  **Africa**                                                                                                                                                                                                                                                                                                                                                                                                  

  Amoo and Ogunlesi[@b81-ndt-12-357]        Nigeria                      NR               NGN 2005[a](#tfn1-ndt-12-357){ref-type="table-fn"}    P                                     PB               Bottom-up                        NR                                Aro Neuropsychiatric Hospital and the Federal Medical Centre, Abeokuta                    6 months                                  57

  Suleiman et al[@b82-ndt-12-357]           Nigeria                      NR               NGN 1997[a](#tfn1-ndt-12-357){ref-type="table-fn"}\   P                                     PB               Bottom-up                        NA                                Yaba Psychiatric Hospital                                                                 6 months                                  50
                                                                                          USD 1997[a](#tfn1-ndt-12-357){ref-type="table-fn"}                                                                                                                                                                                                                                                                  

  **Asia Pacific**                                                                                                                                                                                                                                                                                                                                                                                            

  Carr et al[@b70-ndt-12-357]               Australia                    Payer societal   AUD 2000                                              P                                     PB               Bottom-up                        Human capital                     Four metropolitan Australian Capital Territory, Queensland, Victoria, Western Australia   1997--1998                                980

  Fitzgerald et al[@b80-ndt-12-357]         Australia                    NR               AUD 2007[a](#tfn1-ndt-12-357){ref-type="table-fn"}    P                                     PB               Bottom-up                        Human capital                     As part of the Australian SCAP                                                            3 years                                   347

  Hall et al[@b72-ndt-12-357]               Australia                    NR               USD 1975                                              R                                     IB               Top-down and bottom-up           Human capital                     New South Wales                                                                           1974--1977                                NR

  Langley-Hawthorne[@b79-ndt-12-357]        Australia                    NR               AUD 1997[a](#tfn1-ndt-12-357){ref-type="table-fn"}    Markov model                          IB               Bottom-up                        Human capital                     National                                                                                  NA                                        NR

  Zhai et al[@b78-ndt-12-357]               People's Republic of China   NR               USD 2013[a](#tfn1-ndt-12-357){ref-type="table-fn"}    P                                     PB               Bottom-up                        Human capital                     Two centers in North and South China                                                      2010                                      356

  Grover et al[@b71-ndt-12-357]             India                        NR               INR 2005[a](#tfn1-ndt-12-357){ref-type="table-fn"}    P                                     PB               Bottom-up                        Human capital                     Departments of psychiatry and endocrinology of a tertiary hospital                        NR                                        50

  Pahuja et al[@b75-ndt-12-357]             India                        NR               INR 2011[a](#tfn1-ndt-12-357){ref-type="table-fn"}    P                                     PB               Bottom-up                        NA                                A tertiary care hospital in Kerala, India                                                 6 months                                  25

  Sado et al[@b77-ndt-12-357]               Japan                        Societal         JPY 2008\                                             CS                                    PB               Top-down                         Human capital                     National                                                                                  2008                                      NR
                                                                                          USD 2008                                                                                                                                                                                                                                                                                                            

  Chang et al[@b11-ndt-12-357]              South Korea                  Societal         USD 2005                                              R                                     PB               Top-down                         Human capital                     National                                                                                  2005                                      161,058

  de Silva et al[@b69-ndt-12-357]           Sri Lanka                    NR               LKR 2012[a](#tfn1-ndt-12-357){ref-type="table-fn"}    P                                     PB               Bottom-up                        Human capital                     Outpatient psychiatry clinic of the National Hospital of Sri Lanka                        2 months                                  91

  Lang and Su[@b73-ndt-12-357]              Taiwan                       NR               USD 1999                                              R                                     PB               Top-down                         NA                                National                                                                                  NR                                        52,432

  Lee et al[@b74-ndt-12-357]                Taiwan                       Societal         USD 1999                                              P                                     PB               Bottom-up                        Human capital                     Psychiatric outpatient clinics in three cities: Tainan, Chiayi, Changhua                  August 1999--May 2000                     74

  Phanthunane et al[@b76-ndt-12-357]        Thailand                     Societal         THB 2008                                              P                                     PB               Bottom-up                        Human capital                     Nine hospitals                                                                            September to November 2008                429

  **Europe**                                                                                                                                                                                                                                                                                                                                                                                                  

  De Hert et al[@b30-ndt-12-357]            Belgium                      NR               USD 1994                                              P                                     PB               Bottom-up                        NA                                Four psychiatrists' agendas and six hospital wards                                        1994                                      108

  Mangalore and Knapp[@b42-ndt-12-357]      England                      Societal         GBP 2007[a](#tfn1-ndt-12-357){ref-type="table-fn"}\   R                                     PB               Bottom-up                        Human capital                     As part of UK SCAP                                                                        NR                                        600
                                                                                          EUR 2007[a](#tfn1-ndt-12-357){ref-type="table-fn"}\                                                                                                                                                                                                                                                                 
                                                                                          USD 2007[a](#tfn1-ndt-12-357){ref-type="table-fn"}                                                                                                                                                                                                                                                                  

  Rouillon[@b44-ndt-12-357]                 France                       Payer            USD 1992                                              CS                                    PB               Bottom-up                        NA                                National                                                                                  November 1992                             477

  Sarlon et al[@b48-ndt-12-357]             France                       NR               EUR 2007                                              P                                     PB               Top-down and bottom-up           Human capital                     Three integrated areas in northern, central, and southern France                          2 years                                   288

  Heider et al[@b38-ndt-12-357]             France\                      Payer            EUR 2000                                              P                                     PB               Top-down and bottom-up           NA                                Three centers in France, four centers in Germany, and two centers in the UK               1998--2002                                1,208
                                            Germany\                                                                                                                                                                                                                                                                                                                                                          
                                            UK                                                                                                                                                                                                                                                                                                                                                                

  Frey[@b33-ndt-12-357]                     Germany                      Societal payer   EUR 2008                                              R                                     PB               Bottom-up                        Friction cost                     National                                                                                  2005--2008                                8,224

  Salize and Rossler[@b47-ndt-12-357]       Germany                      NR               USD 1994                                              P                                     PB               Bottom-up                        NA                                Two hospitals                                                                             1 year                                    66

  Zeidler et al[@b51-ndt-12-357]            Germany                      Payer            EUR 2006                                              R                                     PB               Bottom-up                        NA                                One insurance scheme                                                                      2004--2006                                9,946

  Behan et al[@b52-ndt-12-357]              Ireland                      NR               EUR 2006                                              R                                     PB               Top-down and bottom-up           Human capital                     National                                                                                  2006                                      10,126

  Garattini[@b34-ndt-12-357]                Italy                        Payer            EUR 1997                                              R                                     PB               Bottom-up                        NA                                14 CMHCs                                                                                  September to December 1998                702

  Garattini et al[@b35-ndt-12-357]          Italy                        Payer            USD 1998                                              P                                     PB               Bottom-up                        NA                                14 CMHCs                                                                                  1 year                                    643

  Tarricone et al[@b49-ndt-12-357]          Italy                        NR               ITL 1995                                              R                                     PB               Bottom-up                        Human capital                     10 CMHCs                                                                                  1995                                      100

  Evers and Ament[@b53-ndt-12-357]          the Netherlands              Societal         ANG 1989                                              R                                     PB               Top-down                         Human capital                     National                                                                                  1989                                      NR

  Knapp et al[@b40-ndt-12-357]              the Netherlands\             NR               GBP 2002[a](#tfn1-ndt-12-357){ref-type="table-fn"}    R                                     PB               Bottom-up                        NA                                NR                                                                                        3 months                                  404
                                            Denmark\                                                                                                                                                                                                                                                                                                                                                          
                                            UK\                                                                                                                                                                                                                                                                                                                                                               
                                            Italy\                                                                                                                                                                                                                                                                                                                                                            
                                            Spain                                                                                                                                                                                                                                                                                                                                                             

  Rund and Ruud[@b45-ndt-12-357]            Norway                       NR               NOK 1994\                                             P                                     PB               Bottom-up                        NA                                All treatment units serving six catchment areas                                           4 weeks                                   412
                                                                                          USD 1994                                                                                                                                                                                                                                                                                                            

  Saldivia Borquez et al[@b29-ndt-12-357]   Spain                        NR               EUR 1999                                              NR                                    PB               Bottom-up                        NA                                Granada Province                                                                          1999                                      NR

  Haro et al[@b37-ndt-12-357]               Spain                        NR               USD 1994                                              P                                     PB               Top-down and bottom-up           Human capital                     Three areas: Burlada, Cantabria, the Eixample                                             NR                                        112

  Oliva-Moreno et al[@b43-ndt-12-357]       Spain                        Payer            EUR 2002                                              R                                     PB               Top-down                         NA                                National                                                                                  2002                                      NR

  Vazquez-Polo et al[@b50-ndt-12-357]       Spain                        Societal payer   EUR 1997                                              Markov Chain Monte Carlo simulation   PB               Bottom-up                        NR                                Four areas: Catalonia, Andalusia, Madrid, Navarre                                         3-year follow-up from 1997 (1998--2000)   356

  Salize et al[@b46-ndt-12-357]             Spain\                       NR               EUR 2004                                              P                                     PB               Bottom-up                        NA                                Community psychiatric services                                                            12 months                                 507
                                            the Netherlands\                                                                                                                                                                                                                                                                                                                                                  
                                            UK\                                                                                                                                                                                                                                                                                                                                                               
                                            Sweden\                                                                                                                                                                                                                                                                                                                                                           
                                            Germany\                                                                                                                                                                                                                                                                                                                                                          
                                            Switzerland                                                                                                                                                                                                                                                                                                                                                       

  Ekman et al[@b32-ndt-12-357]              Sweden                       Societal         EUR 2009                                              R                                     PB               Top-down and bottom-up           Human capital                     National                                                                                  2006--2008                                2,161

  Hertzman[@b39-ndt-12-357]                 Sweden                       NR               SEK 1975                                              NR                                    PB               Top-down                         Human capital                     National                                                                                  1975                                      NR

  Lindstrom et al[@b41-ndt-12-357]          Sweden                       NR               SEK 2005\                                             P                                     PB               Bottom-up                        Human capital                     NR                                                                                        5 years                                   225
                                                                                          EUR 2005                                                                                                                                                                                                                                                                                                            

  Davies and Drummond[@b31-ndt-12-357]      UK                           NR               GBP 1990/1991                                         NR                                    PB/IB            Top-down                         Human capital                     National                                                                                  NR                                        185,400

  Guest and Cookson[@b36-ndt-12-357]        UK                           Societal payer   GBP 1997                                              Discrete event model                  IB               Top-down                         Human capital                     National                                                                                  5 years                                   7,500

  **America**                                                                                                                                                                                                                                                                                                                                                                                                 

  Leitao et al[@b66-ndt-12-357]             Brazil                       NR               USD 1998                                              Decision tree model                   PB               Bottom-up                        NA                                Sao Paulo                                                                                 1998                                      120

  Goeree et al[@b60-ndt-12-357]             Canada                       Societal         CAD 2004                                              R                                     PB               Top-down                         Friction cost                     National                                                                                  2004                                      234,305

  Rubio-Stipec et al[@b65-ndt-12-357]       Puerto Rico                  Societal         USD 1994[a](#tfn1-ndt-12-357){ref-type="table-fn"}    CS                                    PB               Top-down                         Human capital                     National                                                                                  NR                                        NR

  Bartels et al[@b54-ndt-12-357]            US                           NR               USD 1999                                              R                                     PB               Bottom-up                        NA                                New Hampshire                                                                             January 1--December 31, 1999              9,844

  Crown et al[@b55-ndt-12-357]              US                           NR               USD 2001[a](#tfn1-ndt-12-357){ref-type="table-fn"}    R                                     PB               Bottom-up                        NA                                National                                                                                  1991--1993                                665

  Cuffel et al[@b56-ndt-12-357]             US                           NR               USD 1986                                              R                                     PB               Top-down                         NA                                San Diego                                                                                 1986 and 1990                             15,403; 16,206

  Desai et al[@b57-ndt-12-357]              US                           Societal         USD 2008                                              R                                     PB               Bottom-up                        Human capital                     National                                                                                  2005--2008                                348

  Dixon et al[@b58-ndt-12-357]              US                           Payer            USD 2001[a](#tfn1-ndt-12-357){ref-type="table-fn"}    R                                     PB               Bottom-up                        NA                                National                                                                                  1991                                      12,440

  Feldman et al[@b59-ndt-12-357]            US                           NR               USD 2010                                              R                                     PB               Top-down                         NA                                National                                                                                  2003--2008                                36,852

  Gunderson and Mosher[@b68-ndt-12-357]     US                           Societal         USD 1975[a](#tfn1-ndt-12-357){ref-type="table-fn"}    R                                     PB               Bottom-up                        Human capital                     National                                                                                  1968, 1971, 1973                          NR

  Leslie and Rosenheck[@b61-ndt-12-357]     US                           NR               USD 1993                                              R                                     PB               Bottom-up                        NA                                National                                                                                  1993--1995                                3,456; 3,759

  Martin and Miller[@b62-ndt-12-357]        US                           NR               USD 1998[a](#tfn1-ndt-12-357){ref-type="table-fn"}    R                                     PB               Bottom-up                        NA                                Georgia                                                                                   January 1, 1991--December 31, 1993        6,443

  McDonald et al[@b63-ndt-12-357]           US                           NR               USD 2005[a](#tfn1-ndt-12-357){ref-type="table-fn"}    CS                                    PB               Bottom-up                        NA                                National                                                                                  2001--2002                                571,000

  Miller and Martin[@b64-ndt-12-357]        US                           NR               USD 1995                                              R                                     PB               Bottom-up                        NA                                Georgia                                                                                   1990--1997                                16,227

  Wu et al[@b10-ndt-12-357]                 US                           Societal         USD 2002                                              R                                     PB               Top-down and bottom-up           Human capital                     National                                                                                  2000--2003                                NR

  Wyatt et al[@b67-ndt-12-357]              US                           NR               USD 1995[a](#tfn1-ndt-12-357){ref-type="table-fn"}    NR                                    PB               Bottom-up                        NR                                National                                                                                  1991                                      NA
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:**

If no price-year was reported in a study, the year of publication was referred as the year of pricing.

**Abbreviations:** ANG, Dutch guilder; AUD, Australian dollar; CAD, Canadian dollar; CMHC, community mental health center; CS, cross-sectional; EUR, Euro; GBP, British pound; IB, incidence-based; INR, Indian rupee; ITL, Italian lira; JPY, Japanese yen; LKR, Sri Lankan rupee; NA, not applicable; NGN, Nigerian naira; NOK, Norwegian krone; NR, not reported or insufficient information; P, prospective; PB, prevalence-based; R, retrospective; SCAP, schizophrenia care and assessment program; SEK, Swedish krona; THB, Thai baht; USD, US dollar.

###### 

Direct medical cost components and data sources used in cost estimation

  Author                                    Cost components   Data source for utilization data                                                                                           
  ----------------------------------------- ----------------- ---------------------------------- ---- ---- ---- ---- ---- ---- ------------------------------------------ ---- ---- ---- ----
  **Africa**                                                                                                                                                                             
  Amoo and Ogunlesi[@b81-ndt-12-357]        −                 −                                  −    \+   \+   \+   −    −    Registration fees, feeding/bedding              √         
  Suleiman et al[@b82-ndt-12-357]           −                 \+                                 −    \+   \+   −    −    −    --                                              √         
  **Asia Pacific**                                                                                                                                                                       
  Carr et al[@b70-ndt-12-357]               \+                \+                                 \+   \+   \+   −    −    \+   Out-of-pocket expenditure                                 √
  Fitzgerald et al[@b80-ndt-12-357]         \+                \+                                 \+   −    \+   −    −    \+   --                                         √              
  Hall et al[@b72-ndt-12-357]               −                 −                                  −    −    −    −    −    −    Unspecified                                          √    √
  Langley-Hawthorne[@b79-ndt-12-357]        \+                \+                                 −    \+   \+   −    −    \+   --                                                   √    
  Zhai et al[@b78-ndt-12-357]               −                 −                                  −    −    \+   −    −    −    Unspecified                                     √         
  Grover et al[@b71-ndt-12-357]             −                 −                                  −    \+   \+   −    −    −    Infrastructure Out-of-pocket expenditure        √    √    
  Pahuja et al[@b75-ndt-12-357]             \+                −                                  −    \+   \+   \+   −    −    --                                                   √    
  Sado et al[@b77-ndt-12-357]               \+                \+                                 −    −    −    −    −    −    --                                                        √
  Chang et al[@b11-ndt-12-357]              \+                \+                                 −    −    \+   −    −    \+   --                                         √              √
  de Silva et al[@b69-ndt-12-357]           −                 −                                  −    \+   \+   −    −    −    Alternative treatment                           √         
  Lang and Su[@b73-ndt-12-357]              −                 −                                  −    −    \+   −    −    \+   --                                         √              
  Lee et al[@b74-ndt-12-357]                \+                \+                                 \+   −    \+   −    −    \+   Alternative treatment                           √         
  Phanthunane et al[@b76-ndt-12-357]        \+                \+                                 −    −    \+   −    −    −    Nonmedication therapy                           √    √    
  **Europe**                                                                                                                                                                             
  De Hert et al[@b30-ndt-12-357]            \+                −                                  −    \+   \+   −    −    −    --                                              √    √    
  Mangalore and Knapp[@b42-ndt-12-357]      \+                −                                  \+   \+   \+   −    \+   \+   --                                         √              
  Rouillon[@b44-ndt-12-357]                 \+                −                                  −    \+   \+   −    −    −    Intermediate facilities                         √         √
  Sarlon et al[@b48-ndt-12-357]             \+                −                                  −    \+   \+   −    \+   \+   --                                         √    √         
  Heider et al[@b38-ndt-12-357]             \+                −                                  −    \+   \+   −    \+   −    --                                         √    √         
  Frey[@b33-ndt-12-357]                     −                 −                                  \+   −    \+   \+   −    \+   Out-of-pocket expenditure                  √              
  Salize and Rossler[@b47-ndt-12-357]       \+                \+                                 −    −    \+   −    −    −    --                                                   √    
  Zeidler et al[@b51-ndt-12-357]            \+                \+                                 −    −    \+   −    −    −    Unspecified                                √              
  Behan et al[@b52-ndt-12-357]              \+                \+                                 \+   \+   \+   −    \+   \+   --                                         √              √
  Garattini[@b34-ndt-12-357]                \+                \+                                 −    −    \+   \+   \+   \+   --                                              √         
  Garattini et al[@b35-ndt-12-357]          \+                \+                                 −    −    \+   \+   \+   \+   --                                              √         
  Tarricone et al[@b49-ndt-12-357]          \+                −                                  −    \+   \+   \+   −    \+   Out-of-pocket expenditure                       √         
  Evers and Ament[@b53-ndt-12-357]          \+                \+                                 −    \+   \+   −    \+   −    --                                                        √
  Knapp et al[@b40-ndt-12-357]              \+                \+                                 −    −    −    −    \+   \+   --                                              √         
  Rund and Ruud[@b45-ndt-12-357]            \+                \+                                 −    −    −    −    \+   \+   --                                              √         
  Saldivia Borquez et al[@b29-ndt-12-357]   \+                \+                                 −    \+   \+   −    −    −    Infrastructure                             NR   NR   NR   NR
  Haro et al[@b37-ndt-12-357]               \+                \+                                 −    −    −    \+   −    \+   --                                         √    √    √    
  Oliva-Moreno et al[@b43-ndt-12-357]       \+                \+                                 \+   −    \+   −    \+   \+   --                                         √         √    √
  Vazquez-Polo et al[@b50-ndt-12-357]       \+                −                                  \+   \+   \+   −    −    −    Alternative treatment                           √         
  Salize et al[@b46-ndt-12-357]             \+                \+                                 −    −    \+   −    \+   \+   --                                                   √    
  Ekman et al[@b32-ndt-12-357]              \+                \+                                 −    −    \+   −    −    \+   --                                         √              √
  Hertzman[@b39-ndt-12-357]                 \+                \+                                 −    −    \+   −    −    −    --                                                        √
  Lindstrom et al[@b41-ndt-12-357]          \+                −                                  −    −    \+   −    −    −    --                                         NR   NR   NR   NR
  Davies and Drunmmond[@b31-ndt-12-357]     −                 \+                                 −    −    \+   −    −    \+   --                                                        √
  Guest and Cookson[@b36-ndt-12-357]        \+                −                                  \+   \+   \+   −    \+   \+   --                                              √         √
  **America**                                                                                                                                                                            
  Leitao et al[@b66-ndt-12-357]             \+                \+                                 −    −    −    −    −    \+   --                                         √    √    √    √
  Goeree et al[@b60-ndt-12-357]             \+                −                                  \+   \+   \+   −    −    \+   --                                         √              √
  Rubio-Stipec et al[@b65-ndt-12-357]       −                 −                                  −    −    −    −    −    −    Unspecified                                               √
  Bartels et al[@b54-ndt-12-357]            \+                \+                                 −    \+   \+   −    −    \+   Insurance-related                          √              
  Crown et al[@b55-ndt-12-357]              \+                \+                                 −    −    \+   −    −    −    --                                         √              
  Cuffel et al[@b56-ndt-12-357]             \+                \+                                 −    −    \+   −    \+   \+   --                                         √              
  Desai et al[@b57-ndt-12-357]              \+                \+                                 \+   −    \+   −    −    \+   --                                         √              
  Dixon et al[@b58-ndt-12-357]              −                 −                                  −    −    −    −    −    −    --                                         √              
  Feldman et al[@b59-ndt-12-357]            \+                \+                                 −    \+   \+   −    −    \+   --                                         √              
  Gunderson and Mosher[@b68-ndt-12-357]     \+                \+                                 −    \+   −    −    \+   \+   Construction                               √              √
  Leslie and Rosenheck[@b61-ndt-12-357]     \+                \+                                 −    −    −    −    −    −    --                                         √              
  Martin and Miller[@b62-ndt-12-357]        \+                \+                                 −    \+   −    \+   \+   \+   --                                         √              
  McDonald et al[@b63-ndt-12-357]           \+                −                                  \+   −    \+   −    −    \+   --                                         √              
  Miller and Martin[@b64-ndt-12-357]        \+                −                                  −    \+   \+   −    −    \+   --                                         √              
  Wu et al[@b10-ndt-12-357]                 \+                \+                                 −    \+   \+   −    −    \+   --                                         √              
  Wyatt et al[@b67-ndt-12-357]              \+                −                                  −    −    \+   −    −    \+   Substance abuse                            √    √    √    √

**Notes:**

Includes physician, psychiatrist, psychologist, and other health care provider fee.

Includes medical equipment.

Includes nursing home, long-term institutional, and rehabilitation care. + included; − not included; √ data source used.

**Abbreviation:** NR, not reported or insufficient information.

###### 

Direct nonmedical cost components and data sources used in cost estimation

  Author                                  Cost component   Data sources for utilization data                                                                                 
  --------------------------------------- ---------------- ----------------------------------- ---- ---- ---------------------------------------------------- ---- ---- ---- ----
  **Africa**                                                                                                                                                                 
  Amoo and Ogunlesi[@b81-ndt-12-357]      −                −                                   \+   −    Pocket money for patients and nurses                      √         
  Suleiman et al[@b82-ndt-12-357]         −                −                                   \+   −    --                                                        √         
  **Asia Pacific**                                                                                                                                                           
  Carr et al[@b70-ndt-12-357]             \+               \+                                  −    −    --                                                                  √
  Langley-Hawthorne[@b79-ndt-12-357]      \+               −                                   −    −    --                                                                  √
  Zhai et al[@b78-ndt-12-357]             −                −                                   −    −    Unspecified                                               √         
  Grover et al[@b71-ndt-12-357]           −                −                                   \+   −    --                                                        √         
  Sado et al[@b77-ndt-12-357]             −                \+                                  −    −    --                                                                  √
  Chang et al[@b11-ndt-12-357]            \+               −                                   \+   −    --                                                                  √
  de Silva et al[@b69-ndt-12-357]         −                −                                   \+   −    --                                                        √         
  Lee et al[@b74-ndt-12-357]              \+               \+                                  \+   −    Community resources                                       √         
  Phanthunane et al[@b76-ndt-12-357]      −                −                                   \+   −    --                                                        √         
  **Europe**                                                                                                                                                                 
  De Hert et al[@b30-ndt-12-357]          \+               −                                   −    −    --                                                        √         
  Mangalore and Knapp[@b42-ndt-12-357]    \+               \+                                  −    −    --                                                   √              √
  Rouillon[@b44-ndt-12-357]               −                \+                                  −    −    --                                                        √         √
  Frey[@b33-ndt-12-357]                   −                −                                   \+   −    Housekeeping, administrative, hospital investments   √              
  Salize and Rossler[@b47-ndt-12-357]     \+               −                                   −    −    --                                                             √    
  Behan et al[@b52-ndt-12-357]            \+               \+                                  −    −    --                                                                  √
  Evers and Ament[@b53-ndt-12-357]        \+               −                                   −    −    --                                                                  √
  Knapp et al[@b40-ndt-12-357]            \+               −                                   −    −    --                                                        √         
  Vazquez-Polo et al[@b50-ndt-12-357]     \+               \+                                  −    −    --                                                        √         
  Salize et al[@b46-ndt-12-357]           \+               −                                   −    −    --                                                             √    
  Lindstrom et al[@b41-ndt-12-357]        \+               −                                   −    −    --                                                   NR   NR   NR   NR
  Guest and Cookson[@b36-ndt-12-357]      \+               −                                   −    −    --                                                        √         √
  **America**                                                                                                                                                                
  Goeree et al[@b60-ndt-12-357]           \+               −                                   −    \+   --                                                                  √
  Gunderson and Mosher[@b68-ndt-12-357]   −                −                                   −    −    Research                                                            √
  Martin and Miller[@b62-ndt-12-357]      −                −                                   \+   −    --                                                   √              
  Wu et al[@b10-ndt-12-357]               \+               −                                   −    −    Research and training                                               √
  Wyatt et al[@b67-ndt-12-357]            \+               −                                   −    \+   --                                                        √         √

**Notes:** + included; − not included; √ data source used.

**Abbreviations:** NGO, non-governmental organization; NR, not reported or insufficient information.

###### 

Indirect cost components and data sources used in cost estimation

  Author                                  Cost component   Data sources for utilization data                                                                                                           
  --------------------------------------- ---------------- ----------------------------------- ---- ---- ---- ---- ---- ---- ---- ----------------------------------------------------- ---- ---- ---- ----
  **Africa**                                                                                                                                                                                           
  Amoo and                                −                −                                   \+   −    −    −    −    −    \+   --                                                         √         
  Ogunlesi[@b81-ndt-12-357]                                                                                                                                                                            
  Suleiman et al[@b82-ndt-12-357]         −                −                                   −    −    −    −    −    \+   \+   Accident and damages, unspecified productivity loss        √         
  **Asia Pacific**                                                                                                                                                                                     
  Carr et al[@b70-ndt-12-357]             −                −                                   −    \+   −    \+   \+   −    \+   Tax foregone, unspecified productivity loss                          √
  Fitzgerald et al[@b80-ndt-12-357]       −                −                                   −    −    −    \+   \+   −    −    Tax foregone, unspecified productivity loss           √    √         √
  Hall et al[@b72-ndt-12-357]             −                −                                   −    −    −    −    −    −    −    Unspecified productivity loss                                        √
  Langley-Hawthorne[@b79-ndt-12-357]      −                −                                   \+   −    −    \+   −    −    −    --                                                                   √
  Zhai et al[@b78-ndt-12-357]             \+               −                                   −    \+   \+   −    −    −    \+   Accident and damages                                       √         
  Grover et al[@b71-ndt-12-357]           \+               −                                   −    −    −    −    −    −    \+   Unspecified productivity loss                              √         
  Sado et al[@b77-ndt-12-357]             −                −                                   \+   \+   \+   −    −    −    −    --                                                         √         √
  Chang et al[@b11-ndt-12-357]            −                \+                                  \+   −    \+   −    −    \+   \+   --                                                                   √
  de Silva et al[@b69-ndt-12-357]         \+               −                                   \+   −    −    −    −    −    \+   Unspecified productivity loss                              √         
  Lee et al[@b74-ndt-12-357]              −                −                                   −    −    −    −    −    −    \+   --                                                         √         
  Phanthunane et al[@b76-ndt-12-357]      \+               \+                                  −    −    −    −    −    −    \+   --                                                         √         
  **Europe**                                                                                                                                                                                           
  Mangalore and Knapp[@b42-ndt-12-357]    \+               −                                   \+   −    \+   −    −    \+   \+   --                                                    √              √
  Sarlon et al[@b48-ndt-12-357]           \+               −                                   \+   −    −    −    −    −    −    --                                                         √         
  Frey[@b33-ndt-12-357]                   \+               −                                   −    \+   \+   −    −    −    \+   --                                                    √              √
  Behan et al[@b52-ndt-12-357]            \+               −                                   \+   −    \+   −    −    \+   \+   --                                                    √              √
  Tarricone et al[@b49-ndt-12-357]        \+               −                                   −    −    −    −    −    −    \+   --                                                         √         
  Evers and Ament[@b53-ndt-12-357]        \+               −                                   −    \+   −    −    −    −    −    --                                                                   √
  Haro et al[@b37-ndt-12-357]             −                −                                   −    −    −    −    −    −    \+   Unspecified productivity loss                         NR   NR   NR   NR
  Oliva-Moreno et al[@b43-ndt-12-357]     −                −                                   −    −    −    −    −    −    \+   --                                                                   √
  Ekman et al[@b32-ndt-12-357]            \+               −                                   −    \+   −    −    −    −    −    --                                                                   √
  Hertzman[@b39-ndt-12-357]               −                −                                   −    \+   \+   −    −    −    −    Short-term illness                                                   √
  Lindstrom et al[@b41-ndt-12-357]        −                −                                   −    −    −    −    −    −    −    Unspecified productivity loss                         NR   NR   NR   NR
  Davies and Drummond[@b31-ndt-12-357]    −                −                                   \+   −    −    −    −    −    −    Unspecified productivity loss                         NR   NR   NR   NR
  Guest and Cookson[@b36-ndt-12-357]      \+               −                                   \+   −    \+   −    −    \+   \+   --                                                         √         √
  **America**                                                                                                                                                                                          
  Goeree et al[@b60-ndt-12-357]           −                −                                   −    \+   \+   \+   −    \+   −    --                                                                   √
  Rubio-Stipec et al[@b65-ndt-12-357]                                                               −    −    −    −    −    −    Unspecified productivity loss                                        √
  Desai et al[@b57-ndt-12-357]            \+               \+                                  −    −    \+   −    −    −    \+   --                                                    √    √         √
  Gunderson and Mosher[@b68-ndt-12-357]   −                −                                   −    −    −    \+   −    −    −    Unspecified productivity loss                                        √
  Wu et al[@b10-ndt-12-357]               \+               \+                                  \+   −    \+   −    −    \+   \+   --                                                                   √
  Wyatt et al[@b67-ndt-12-357]            −                −                                   −    −    \+   \+   \+   −    \+   Unspecified productivity loss                              √         

**Notes:**

Includes permanent disability and early retirement.

Includes incarceration, crime, and police contact. + included; − not included; √ data source used.

**Abbreviation:** NR, not reported or insufficient information.

###### 

Annual cost estimate of direct and indirect costs and total cost as % of GDP (USD 2013) in national studies

  Author                                  Country           Cost estimates (USD 2013, millions)   Cost contribution to total cost (%)   Total cost as % GDP (USD 2013)                               
  --------------------------------------- ----------------- ------------------------------------- ------------------------------------- -------------------------------- --------- ---- ------- ---- ------
  **Asia Pacific**                                                                                                                                                                                   
  Sado et al[@b77-ndt-12-357]             Japan             7,247                                 33                                    18,950                           26,230    28   \<0.1   72   0.52
  Chang et al[@b11-ndt-12-357]            South Korea       519                                   36                                    3,204                            3,759     14   1       85   0.31
  **Europe**                                                                                                                                                                                         
  Behan et al[@b52-ndt-12-357]            Ireland           172                                   13                                    488                              673       25   2       73   0.30
  Frey[@b33-ndt-12-357]                   Germany           10,635                                354                                   8,978                            19,967    53   2       45   0.56
  Evers and Ament[@b53-ndt-12-357]        the Netherlands   774                                   50                                    70                               894       87   6       8    0.11
  Olivia-Moreno et al[@b43-ndt-12-357]    Spain             1,882                                 NA                                    1,669                            3,552     53   NA      47   0.26
  Ekman et al[@b32-ndt-12-357]            Sweden            29                                    NA                                    94                               123       24   NA      76   0.02
  Hertzman[@b39-ndt-12-357]               Sweden            3,712                                 NA                                    5,422                            9,134     41   NA      59   1.65
  Guest and Cookson[@b36-ndt-12-357]      UK                154                                   49                                    199                              403       38   12      50   0.02
  **America**                                                                                                                                                                                        
  Goeree et al[@b60-ndt-12-357]           Canada            2,111                                 102                                   5,287                            7,500     28   \<0.1   72   0.41
  Rubio-Stipec et al[@b65-ndt-12-357]     Puerto Rico       31                                    NA                                    63                               94        33   NA      67   0.09
  Desai et al[@b57-ndt-12-357]            US                4,742                                 NA                                    20,710                           25,452    19   NA      81   0.15
  Wu et al[@b10-ndt-12-357]               US                29,279                                12,014                                41,714                           83,007    35   14      50   0.50
  Wyatt et al[@b67-ndt-12-357]            US                27,745                                4,054                                 70,597                           102,396   27   4       69   0.61
  Gunderson and Mosher[@b68-ndt-12-357]   US                12,078                                57                                    48,200                           60,335    20   \<0.1   80   0.36

**Abbreviations:** GDP, gross domestic product; NA, not applicable; USD, US dollar.

###### 

Annual cost estimate of direct and indirect costs in LMIC

  Author                               Country                      Cost estimates (USD 2013)                          Cost contribution to total cost (%)                                                                                   
  ------------------------------------ ---------------------------- -------------------------------------------------- ------------------------------------- ------------ ------------ ----------------------------------------------- ----- ----
  Amoo and Ogunlesi[@b81-ndt-12-357]   Nigeria                      9,882[a](#tfn13-ndt-12-357){ref-type="table-fn"}   NR                                    3,604        13,486       73[a](#tfn13-ndt-12-357){ref-type="table-fn"}   NR    27
  Suleiman et al[@b82-ndt-12-357]      Nigeria                      2,951                                              80                                    430          3,461        85                                              2     12
  Zhai et al[@b78-ndt-12-357]          People's Republic of China   257,980                                            44,237                                515,297      817,514      32                                              5     63
  Grover et al[@b71-ndt-12-357]        India                        1,814                                              718                                   4,310        6,842        27                                              10    63
  de Silva et al[@b69-ndt-12-357]      Sri Lanka                    25,075                                             186                                   111,574      136,834      18                                              0.1   82
  Phanthunane et al[@b76-ndt-12-357]   Thailand                     6,661,900                                          521,900                               17,613,000   24,796,800   27                                              2     71

**Note:**

Includes direct nonmedical cost.

**Abbreviations:** USD, US dollar; NR, not reported or insufficient information; LMIC, low- and middle-income countries.
